These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32826471)

  • 1. A report on Lineage switch at relapse of CD19 CAR-T therapy for Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
    Li LZ; Sun Q; Fang Y; Yang LJ; Xu ZY; Hu JH; Cao L; Huang JY; Hong M; Li JY; Qian SX
    Chin Med J (Engl); 2020 Aug; 133(16):2001-2003. PubMed ID: 32826471
    [No Abstract]   [Full Text] [Related]  

  • 2. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
    He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
    [No Abstract]   [Full Text] [Related]  

  • 3. CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months.
    Yao Z; Gu B; Chen J; Xu Y; Chen F; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Yu L; Zhang Y; Wu D; Wang Y
    Blood Cancer J; 2023 May; 13(1):75. PubMed ID: 37164955
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19.
    Acharya L; Garg A; Rai M; Kshetri R; Grewal US; Dhakal P
    J Investig Med; 2024 Jan; 72(1):32-46. PubMed ID: 37497999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yao Z; Gu B; Zhang Y; Qi J; Chen J; Xu Y; Chen F; Ma X; Miao M; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Yu L; Wu D; Wang Y
    Bone Marrow Transplant; 2023 Jan; 58(1):103-105. PubMed ID: 36253466
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.
    Xu X; Sun Q; Liang X; Chen Z; Zhang X; Zhou X; Li M; Tu H; Liu Y; Tu S; Li Y
    Front Immunol; 2019; 10():2664. PubMed ID: 31798590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
    Geyer MB; Manjunath SH; Evans AG; Park JH; Davila ML; Cutler CS; Wang X; Wang Y; Senechal B; Rivière I; Sadelain M; Liesveld JL; Brentjens RJ
    Leuk Lymphoma; 2018 Jul; 59(7):1717-1721. PubMed ID: 29043880
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation.
    Yang F; Yang X; Bao X; Kang L; Zhou L; Wu X; Tang X; Fu Z; Ma X; Sun A; Zhang J; Qiu H; Wu D
    Leuk Lymphoma; 2020 Feb; 61(2):429-436. PubMed ID: 31512942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.
    El Chaer F; Holtzman NG; Sausville EA; Law JY; Lee ST; Duong VH; Baer MR; Koka R; Singh ZN; Hardy NM; Emadi A
    Acta Haematol; 2019; 141(2):107-110. PubMed ID: 30695783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of CML-transformed B Cell Acute Lymphoblastic Leukemia (B-ALL) in Adults with Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy.
    Liu F; Sha S; Ma G; Su Y; Xiong Y; He G; Li Y; Hanes WM; Tse W
    Stem Cell Rev Rep; 2020 Dec; 16(6):1356-1358. PubMed ID: 32840736
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
    Leahy AB; Devine KJ; Li Y; Liu H; Myers R; DiNofia A; Wray L; Rheingold SR; Callahan C; Baniewicz D; Patino M; Newman H; Hunger SP; Grupp SA; Barrett DM; Maude SL
    Blood; 2022 Apr; 139(14):2173-2185. PubMed ID: 34871373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
    Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
    [No Abstract]   [Full Text] [Related]  

  • 17. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
    Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New European approval: Brexucabtagene autoleucel in adult relapsed/refractory acute lymphoblastic leukemia].
    Lemoine J; Marchand T
    Bull Cancer; 2022 Dec; 109(12):1232-1233. PubMed ID: 36270817
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
    Orlando EJ; Han X; Tribouley C; Wood PA; Leary RJ; Riester M; Levine JE; Qayed M; Grupp SA; Boyer M; De Moerloose B; Nemecek ER; Bittencourt H; Hiramatsu H; Buechner J; Davies SM; Verneris MR; Nguyen K; Brogdon JL; Bitter H; Morrissey M; Pierog P; Pantano S; Engelman JA; Winckler W
    Nat Med; 2018 Oct; 24(10):1504-1506. PubMed ID: 30275569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.